ERBB2 and neoplasm: Through visual‐based assessment of intra‐tumour heterogeneity, 35% of HER2‐positive tumours have mixed tumour architectures associated with heterogeneous cellular patterns ‘mixed architecture heterogeneity’, 12% showed mixed cytoplasmic features, 23% showed mixed cell membrane pattern.